Treatment of Alopecia Areata with Oral JAK Inhibitor: Focusing on Clinical Outcomes with Baricitinib

December 2022 in “ The Nishinihon Journal of Dermatology ”

Yutaka Shimomura, Taisuke Ito, Yoshitaka Isaka, Atsushi Nishikawa, Yumiko NISHIKAWA, Toshihiko Aranishi, Hitoe Torisu‐Itakura, Manabu Ohyama

TLDR Baricitinib is an effective treatment for severe alopecia areata.

Baricitinib, an oral JAK1/2 inhibitor, was developed as a novel treatment for alopecia areata, focusing on its clinical outcomes. Based on results from an international Phase 3 trial, it was approved in Japan in June 2022 for treating alopecia areata, specifically in cases where hair loss was extensive and difficult to treat. While JAK inhibitors required careful consideration of adverse events such as infections and a balance of risks and benefits tailored to individual patients, they were expected to be a useful treatment option for alopecia areata.

View this study on jstage.jst.go.jp →

Discuss this study in the Community →

Research cited in this study

17 / 17 results

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research A Comprehensive Literature Review of JAK Inhibitors in the Treatment of Alopecia Areata

40 citations , June 2021 in “Clinical, cosmetic and investigational dermatology”

JAK inhibitors show promise in effectively treating hair loss from alopecia areata.

Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan

research Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan

7 citations , January 2021 in “Dermatology and therapy”

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

research Development of Clinician-Reported Outcome and Patient-Reported Outcome Measures for Eyebrow, Eyelash, and Nail Assessment in Alopecia Areata

56 citations , August 2020 in “American Journal of Clinical Dermatology”

New tools help assess eyebrow, eyelash, and nail changes in Alopecia Areata, improving understanding of patient experiences.

research The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials

86 citations , January 2020 in “British Journal of Dermatology”

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

research JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis

130 citations , February 2019 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata

55 citations , October 2015 in “Journal of Investigative Dermatology”

Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.

research Alopecia Areata Profiling Shows TH1, TH2, and IL-23 Cytokine Activation Without Parallel TH17/TH22 Skewing

176 citations , August 2015 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology”

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

Alopecia areata is caused by the immune system attacking hair follicles.

research Inhibiting Janus Kinases to Treat Alopecia Areata

52 citations , September 2014 in “Nature medicine”

JAK inhibitors might help treat alopecia areata.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.

research Overview of Alopecia Areata

110 citations , December 2013 in “The journal of investigative dermatology. Symposium proceedings/The Journal of investigative dermatology symposium proceedings”

Alopecia areata is a genetic and immune-related hair loss condition that is often associated with other autoimmune diseases and does not typically cause permanent damage to hair follicles.

Alopecia Areata: An Autoimmune Disease Causing Hair Loss

Related Research

1 / 1 results

research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib

4 citations , July 2018 in “PubMed”

Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.